eTable 1. Site Listings
eTable 2. Survey Questions
Boiselle PM, White CS, Ravenel JG. Computed Tomographic Screening for Lung CancerCurrent Practice Patterns at Leading Academic Medical Centers. JAMA Intern Med. 2014;174(2):286-287. doi:10.1001/jamainternmed.2013.12693
Following the publication of the National Lung Screening Trial (NLST) results,1 several organizations have published clinical practice guidelines (CPGs) for lung cancer screening.1- 4 These guidelines emphasize the clinical aspects of computed tomographic (CT) screening, such as patient selection criteria, with relatively little attention to technical and logistical considerations. We surveyed leading US academic medical centers (AMCs) to determine current screening practices. We hypothesized that there would be greater uniformity in clinical aspects of screening than in technical and logistical elements.
A survey was sent via e-mail in March 2013 to thoracic radiology division chiefs at leading US AMCs, which were identified from the 2012 to 2013 US News & World Report overall ranking of best hospitals (n = 17), top 10 cancer centers, and top 10 pulmonology centers.5 This source was selected because of its use of data from a variety of reputable sources. From the 37 listings, 21 unique sites were identified (eTable 1 in Supplement). Thirteen sites (62%) had participated in prior multicenter lung cancer screening trials. Institutional review board (IRB) approval and informed consent were waived by our institution's IRB director of operations on the basis of the anonymous nature of this survey and the absence of personal protected health information.
The survey (eTable 2 in Supplement) began by inquiring whether the respondent’s site currently offered lung cancer screening and then went on to ask about a variety of screening practices.
Nineteen recipients completed the survey (90% response rate), including 15 sites with a current CT screening program.
Most sites had similar patient selection and referral policies. Eleven of 15 active screening sites (73%) use the NLST entry criteria,1,2 1 uses expanded selection criteria,3,4 and the remaining 3 offer screening to any patients who have participated in shared decision making with a clinical physician (Box). Eleven sites (73%) require a referral from a clinical physician.
National Lung Screening Trial entry criteria
•Age 55 to 74 years
•At least 30 pack-yearsa
•Former smokers must have quit within past 15 years
Expanded screening criteria
•Age at least 50 years
•At least 20 pack-years
•Additional risk factor(s)b
Pack-years calculated as number of cigarette packs smoked per day (20 cigarettes per pack) multiplied by the number of years of smoking.
Additional risk factors for lung cancer defined by the National Comprehensive Cancer Network include cancer history, lung disease history, family history of lung cancer, radon exposure, and occupational exposure.
The most common self-pay charge was in the range of $300 to $400, reported by 10 of 15 respondents (67%). One site (7%) charges more than $400, whereas 3 (20%) charge between $151 and $299 and 1 (7%) charges $150 or less.
The number of patients scanned per week was 1 to 5 at 13 sites (87%), 6 to 10 at 1 site (7%), and more than 20 at 1 site (7%). The estimated dose used was less than 1 mSv at 5 sites (33%), 1 to 2 mSv at 7 sites (47%), and 2 to 3 mSv at 2 sites (13%) (to convert to rems, multiply by 0.1) (on the basis of the wording of this survey question, a dose of precisely 2.0 mSv could apply to a survey response of either 1-2 mSv or 2-3 mSv). One respondent did not know the dose.
For nodule management guidelines, 10 sites (67%) use the Fleischner Society guidelines,6 2 (13%) use the National Comprehensive Cancer Network (NCCN) guidelines, and 1 (7%) uses NLST guidelines.4 The remaining 2 sites use a hybrid approach.
Fourteen sites (93%) include a smoking cessation program, which is mandatory at 3 sites for current smokers.
Our survey results show a high level of uniformity for inclusion of a smoking cessation program. However, there is less uniformity in other parameters, particularly technical elements such as radiation dose that are not covered in most CPGs.1- 3
There is a consensus that screening is appropriate for individuals who meet NLST criteria,1- 4 and 73% of respondents limit screening to this population. Although some guidelines3,4 have expanded their recommendations to other populations at risk, only 1 site is using these criteria. Interestingly, 3 sites offer screening to any patients who have undergone shared decision making with their physicians.
Although respondents reported using 3 different nodule management guidelines, they offer a similar approach for nodules smaller than 8 mm in mean diameter. However, for nodules larger than 8 mm, the Fleischner Society guidelines provide a broader range of options than the NCCN guidelines.4,6 Thus, the greatest likelihood of management differences is for larger nodules, which are more likely to represent lung cancer than smaller nodules.6
By design, we targeted a focused population of leading AMCs to determine whether there is a consensus of “best practices.” We acknowledge that our results may not be representative of all AMCs or of other practice types offering screening in the community setting. In addition, although AMCs are generally early adopters of new practices, we acknowledge that the recent publication of CPGs may have contributed to the lack of uniformity that we observed for some screening practices.
In summary, the lack of uniformity in screening practices reported by leading AMCs suggests the need for formalized radiology guidelines for CT screening for lung cancer. Such guidelines should place primary emphasis on the technical and logistical aspects of screening that are not covered by currently available CPGs. These issues will be addressed in a practice guideline for radiologists that is being developed jointly by the American College of Radiology and the Society of Thoracic Radiology.
Corresponding Author: Phillip Boiselle, MD, Department of Radiology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, TCC-4, Boston, MA 02215 (email@example.com).
Published Online: December 9, 2013. doi:10.1001/jamainternmed.2013.12693.
Author Contributions: Dr Boiselle had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Boiselle.
Acquisition of data: Boiselle.
Analysis and interpretation of data: All authors.
Drafting of the manuscript: Boiselle, Ravenel.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Boiselle.
Administrative, technical, or material support: Ravenel.
Study supervision: Boiselle.
Conflict of Interest Disclosures: None reported.
Correction: This article was corrected online March 10, 2014, for an error in a unit conversion factor.